Dossier assessment
Ravulizumab (atypical haemolytic uraemic syndrome) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ravulizumab (atypical haemolytic uraemic syndrome) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ravulizumab (atypical haemolytic uraemic syndrome) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
| Patients with atypical haemolytic uraemic syndrome who weigh at least 10 kg and are complement inhibitor treatment-naive or have received eculizumab for at least 3 months and have responded to this drug |
Result of dossier assessment:
| Added benefit not proven due to a lack of suitable study data |
Project details
- Project no.
- A20-68
- Commission
- Commission awarded on 28.07.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Ravulizumab (generalized myasthenia gravis) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ravulizumab (neuromyelitis optica spectrum disorder [NMOSD]) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed